Prognostic Significance of Iron Metabolism Related Genes in Human Lung Adenocarcinoma

References

• Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202.
   PubMed Web of Science ®Google Scholar
• Schabath MB, Cote ML. Cancer Progress and Priorities: lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–1579. doi:10.1158/1055-9965.EPI-19-0221
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271. doi:10.3322/caac.21235
   PubMed Web of Science ®Google Scholar
• Lee DG, Kam MK, Lee SR, et al. Peroxiredoxin 5 deficiency exacerbates iron overload-induced neuronal death via ER-mediated mitochondrial fission in mouse hippocampus. Cell Death Dis. 2020;11(3):204. doi:10.1038/s41419-020-2402-7
   Web of Science ®Google Scholar
• Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;2(8191):390–392. doi:10.1016/S0140-6736(80)90440-7
   PubMed Web of Science ®Google Scholar
• Fu Y, Lin L, Xia L. MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1. Cell Mol Biol Lett. 2019;24:31. doi:10.1186/s11658-019-0155-z
   Web of Science ®Google Scholar
• Zhang L, Ye Y, Tu H, et al. MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk. Ann Oncol. 2017;28(5):1124–1129. doi:10.1093/annonc/mdx046
   PubMed Web of Science ®Google Scholar
• Zhao B, Li R, Cheng G, et al. Role of hepcidin and iron metabolism in the onset of prostate cancer. Oncol Lett. 2018;15(6):9953–9958. doi:10.3892/ol.2018.8544
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen J, Feng J, et al. E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin. Cell Death Dis. 2018;9(10):987. doi:10.1038/s41419-018-1001-3
   Google Scholar
• Sornjai W, Nguyen VLF, Pion N, et al. Iron and hepcidin mediate human colorectal cancer cell growth. Chem Biol Interact. 2020;319:109021. doi:10.1016/j.cbi.2020.109021
   Web of Science ®Google Scholar
• Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36(29):4089–4099. doi:10.1038/onc.2017.11
   PubMed Web of Science ®Google Scholar
• Wang Q, Gu T, Ma L, et al. Efficient iron utilization compensates for loss of extracellular matrix of ovarian cancer spheroids. Free Radic Biol Med. 2021;164:369–380. doi:10.1016/j.freeradbiomed.2021.01.001
   Web of Science ®Google Scholar
• Sukiennicki GM, Marciniak W, Muszynska M, et al. Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence. PLoS One. 2019;14(1):e208610. doi:10.1371/journal.pone.0208610
   PubMed Web of Science ®Google Scholar
• Han M, Xu R, Wang S, et al. Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion. Neoplasia. 2018;20(6):543–554. doi:10.1016/j.neo.2018.04.002
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13(5):342–355. doi:10.1038/nrc3495
   PubMed Web of Science ®Google Scholar
• Wen CP, Lee JH, Tai YP, et al. High serum iron is associated with increased cancer risk. Cancer Res. 2014;74(22):6589–6597. doi:10.1158/0008-5472.CAN-14-0360
   Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760. doi:10.1038/nature05236
   PubMed Web of Science ®Google Scholar
• Gu Z, Wang H, Xia J, et al. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015;75(11):2211–2221. doi:10.1158/0008-5472.CAN-14-3804
   PubMed Web of Science ®Google Scholar
• Liu T, Niu X, Li Y, Xu Z, Chen J, Xu G. Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer. World J Surg Oncol. 2022;20(1):96. doi:10.1186/s12957-022-02566-6
   PubMed Web of Science ®Google Scholar
• Kukulj S, Jaganjac M, Boranic M, et al. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol. 2010;27(2):268–277. doi:10.1007/s12032-009-9203-2
   PubMed Web of Science ®Google Scholar
• Xiong W, Wang L, Yu F. Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol. 2014;31(7):28. doi:10.1007/s12032-014-0028-2
   PubMed Web of Science ®Google Scholar
• Pezzuto A, D’Ascanio M, Ricci A, Pagliuca A, Carico E. Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: a review. Thorac Cancer. 2020;11(11):3060–3070. doi:10.1111/1759-7714.13651
   PubMed Web of Science ®Google Scholar
• Pezzuto A, Cappuzzo F, D’Arcangelo M, et al. Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. Anticancer Res. 2020;40(2):983–990. doi:10.21873/anticanres.14032
   PubMed Web of Science ®Google Scholar
• Lee CH, Chen SL, Sung WW, et al. The Prognostic Role of STEAP1 Expression Determined via Immunohistochemistry Staining in Predicting Prognosis of Primary Colorectal Cancer: a Survival Analysis. Int J Mol Sci. 2016;17(4):592. doi:10.3390/ijms17040592
   Web of Science ®Google Scholar
• Gomes IM, Arinto P, Lopes C, et al. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol. 2014;32(1):23–53. doi:10.1016/j.urolonc.2013.08.028
   Web of Science ®Google Scholar
• Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A. 1999;96(25):14523–14528. doi:10.1073/pnas.96.25.14523
   PubMed Web of Science ®Google Scholar
• Rodeberg DA, Nuss RA, Elsawa SF, et al. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res. 2005;11(12):4545–4552. doi:10.1158/1078-0432.CCR-04-2235
   PubMed Web of Science ®Google Scholar
• Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A. 1999;96(25):14523–14528.
   PubMed Web of Science ®Google Scholar
• Grunewald TG, Bach H, Cossarizza A, et al. The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol Cell. 2012;104(11):641–657. doi:10.1111/boc.201200027
   PubMed Web of Science ®Google Scholar
• Chen H, Xu C, Yu Q, et al. Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. J Cell Physiol. 2021;236(4):2988–3000. doi:10.1002/jcp.30060
   Web of Science ®Google Scholar
• Valenti MT, Dalle CL, Donatelli L, et al. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett. 2009;273(1):122–126. doi:10.1016/j.canlet.2008.07.037
   Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241. doi:10.1038/nrclinonc.2015.215
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Xu L, Deng C, Pang B, et al. TIP: a Web Server for Resolving Tumor Immunophenotype Profiling. Cancer Res. 2018;78(23):6575–6580. doi:10.1158/0008-5472.CAN-18-0689
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wang Z, Song Z, et al. Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. Int Immunopharmacol. 2021;101(Pt A):108183. doi:10.1016/j.intimp.2021.108183
   Google Scholar
• Schober SJ, Thiede M, Gassmann H, et al. MHC Class I-Restricted TCR-Transgenic CD4(+) T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo. Cells. 2020;9(7):1581. doi:10.3390/cells9071581
   Web of Science ®Google Scholar
• Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–379. doi:10.1038/cdd.2015.158
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: facts and Hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi:10.1158/1078-0432.CCR-18-1538
   PubMed Web of Science ®Google Scholar
• Zengin T, Onal-Suzek T. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. J Pers Med. 2021;11(2):154. doi:10.3390/jpm11020154
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170(6):1062–1078. doi:10.1016/j.cell.2017.08.028
   PubMed Web of Science ®Google Scholar
• Li L, Li M, Wang X. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA Repair (Amst). 2020;88:102785. doi:10.1016/j.dnarep.2020.102785
   PubMed Web of Science ®Google Scholar
• Gleeson FC, Kipp BR, Levy MJ, et al. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. J Thorac Oncol. 2015;10(3):531–534. doi:10.1097/JTO.0000000000000391
   Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–575. doi:10.1038/nrc2676
   PubMed Web of Science ®Google Scholar
• Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22(11):1045–1054. doi:10.1016/j.phymed.2015.08.002
   PubMed Web of Science ®Google Scholar
• Su Y, Zhao B, Zhou L, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127–136. doi:10.1016/j.canlet.2020.02.015
   PubMed Web of Science ®Google Scholar